Navigation Links
Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference on September 14, 2009
Date:9/10/2009

CRANBURY, N.J., Sept. 10 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company's president and chief executive officer, John F. Crowley, will be presenting at the upcoming Morgan Stanley Global Healthcare Unplugged Conference. Mr. Crowley's presentation is scheduled to begin on Monday, September 14 at 5:05 p.m. EDT.

Individuals can listen to a live webcast of the presentation by logging on to the Investors section of the Amicus Therapeutics' Web site, www.amicustherapeutics.com. Participants should allow approximately five to 10 minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of the webcast will also be available on the Company's Web site for 30 days.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs.


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Retail Industry Leaders Association Files Amicus in California Health Care Litigation
2. Amicus Brief Filed with U.S. Supreme Court in Riegel v. Medtronic, Inc.
3. Oxygen Biotherapeutics, Inc. Posts Latest Blog by CEO Chris Stern
4. Echo Therapeutics Announces New Presentation Time at Rodman & Renshaw 2009 Annual Global Investment Conference
5. New Chief Executive Officer and Vice President Commercial Operations USA at the Helsinn Groups American subsidiary, Helsinn Therapeutics (U.S.) Inc.
6. Cell Therapeutics, Inc.s (CTI) Rodman & Renshaw Healthcare Conference Presentation to be Webcast
7. Reportlinker Adds Autoimmune Disease Therapeutics Report
8. Reportlinker Adds Lung Cancer Therapeutics Report
9. Reportlinker Adds Therapeutics for Memory and Cognition Disorders Report
10. Reportlinker Adds Therapeutics and Diagnostics for Womens Disorders Report
11. Reportlinker Adds Dermatological Therapeutics: Global Markets Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. ... The attorneys chosen by their peers for this recognition are considered among the top ... Shareholders received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... One of Australia,s successful biotechnology ... a new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ... to list on the ASX. Noxopharm is a clinic-ready ... a Phase 1 clinical study later this year. ... the biggest problems facing cancer patients - the ability of cancers ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
Breaking Medicine Technology: